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INTRODUCTION
Brain tumors are themost commonsolid tumorof childhood.The
outcome of childrenwith recurrentmalignant brain tumors is dismal
[1]. High-dose chemotherapy followed by autologous peripheral
blood stem cell rescue (HDC/SCR) has been used for the treatment
of recurrent brain tumors. Several chemotherapy combinations have
been studied. While toxicities have been significant, this approach
has resulted in long-term survival with good quality of life for some
patients [2–7]. Patients with gross residual disease at the time of
HDC/SCRand thosewithmetastatic disease aremuchmore likely to
have disease progression despite this approach [8–13]. Radiation
therapy prior to HDC/SCR may also be associated with a worse
outcome [13–17]. There have also been several studies of 2–4 cycles
of HDC/SCR reported for children with high-risk newly diagnosed
brain tumors [18–20] or recurrent disease [6,21–23].
We report the results of a Phase I trial of tandem HDC/SCR for
recurrentbrain tumors inchildren.Thegoalwasto improveoutcomes
with less toxicity by using two cycles of HDC/SCR at reduced
intensity compared to a single cycle ofHDC/SCR.Thenovel chemo-
therapy regimen used alkylating agents—thiotepa, carboplatin, and
carmustine—which have activity against brain tumors [3,10,24].
Dose escalation of thiotepa in both cycles and of carmustine was
planned. Table I compares the drug doses used for this study versus
those reported for a single HDC/SCR approach by the Children’s
Cancer Group (CCG) [10,24].
METHODS
Patient Eligibility
Patients were eligible if they had a progressive or recurrent brain
tumor including medulloblastoma (MB), ependymoma, high-grade
(III/IV) astrocytoma (HGA), primitive neuroectodermal tumor
(PNET), rhabdoid tumor, or pineoblastoma. Patientswith brain stem
tumors and those who had previous HDC/SCR were not eligible.
Other eligibility criteria included: (1) age1–21years, (2) availability
ofat least4  106CD34þcells/kgofbodyweightavailableforSCR,
(3) creatinine clearance >50 ml/min/1.73 m2 or serum creatinine
<2upper limitofnormal, (4)bilirubin<1.5 mg/dl andSGPT<5
upper limit of normal, (5) FEV1, FVC, andDLCO (corrected)60%
of predicted (no dyspnea on exertion and oxygen saturation 95%
by pulse oximetry on room air if unable to perform spirometry),
(6) cardiac ejection fraction of 50% (by echo or MUGA),
(7) absolute neutrophil count >1,000/ml and platelet count
>100,000/ml, (8) performance score (Lansky or Karnofsky) of
50, (9) no treatment (radiation or chemotherapy) within 3 weeks
of protocol therapy, excluding steroid therapy for increased intra-
cranial pressure. The study was approved by the Internal Review
Committee of the Pediatric Blood and Marrow Transplant
Consortium as well as by the Institutional Review Board of partic-
ipating institutions and informed consent was obtained from the
patient or guardian.
Background.High-dose chemotherapy with autologous stem cell
rescue (HDC/SCR) has produced responses andprolonged survival for
some children with recurrent brain tumors, but is associated with
considerable morbidity and mortality. A Phase I trial of two cycles
of HDC/SCR for recurrent brain tumors in children was performed to
determine the maximum tolerated doses for a novel regimen.
Procedures. Two cycles of HDC/SCR were given. Cycle 1 included
thiotepa and carmustine given on days 5, 4, and 3. Four to six
weeks later, patients received cycle 2 which included thiotepa and
carboplatin given on days 5, 4, and 3. Autologous peripheral
blood stem cells (PBSC) were infused on day 0 of each cycle. Results.
Thirty-twopatientsweretreatedand25patientsreceivedbothcyclesof
HDC/SCR. Common toxicities included mucositis, emesis, diarrhea,
anorexia,andpancytopenia.Eightof32(25%)assessablechildrendied
from regimen-related toxicity. Pulmonary failure occurred in seven
patients.Sevenpatientshadgrade3–4neurotoxicity.The3-yearevent-
free survival (EFS) was 25%. Conclusions. We determined the maxi-
mum tolerated regimen to be thiotepa 600 mg/m2 and carmustine
300 mg/m2 followed by thiotepa 600 mg/m2 and carboplatin
1,200 mg/m2. Pulmonary toxicity was considerable. The toxic death
rate was similar to other trials of HDC/SCR for childrenwith recurrent
brain tumors performed during the same time period. The regimen
resulted in prolonged time to progression for a significant number of
patientsandlong-termsurvival forsomepatientswithrecurrentmedul-
loblastoma and rhabdoid tumor. Pediatr Blood Cancer 2011;57:506–
513.  2010 Wiley-Liss, Inc.
Key words: brain tumors; myeloablative therapy; Phase I clinical trials; stem cell transplantation
1Levine Children’s Hospital, Charlotte, North Carolina; 2Children’s
Hospital of Philadelphia, Philadelphia, Pennsylvania; 3University of
Michigan, Ann Arbor, Michigan; 4Children’s Hospital of Alabama,
Birmingham, Alabama; 5Children’s Hospitals and Clinics of
Minnesota, Minneapolis/St. Paul, Minnesota; 6Nemour’s Children’s
Clinic, Jacksonville, Florida; 7University of Texas MD Anderson
Cancer Center, Houston, Texas; 8St. Christopher’s Hospital for
Children, Philadelphia, Pennsylvania; 9CancerCare Manitoba,
Winnipeg, Manitoba, Canada; 10Children’s Healthcare of Atlanta/
Emory University, Atlanta, Georgia; 11Children’s Mercy Hospital,
Kansas City, Missouri; 12Rady Children’s Hospital, San Diego,
California
Conflict of interest: Nothing to declare.
*Correspondence to: Andrew L. Gilman, MD, Levine Children’s Hospital,
Carolinas Medical Center, 1000 Blythe Blvd., Charlotte, NC 28203.
E-mail: andrew.gilman@carolinashealthcare.org
Received 24 August 2010; Accepted 8 October 2010
 2010 Wiley-Liss, Inc.
DOI 10.1002/pbc.22899
Published online 1 December 2010 in Wiley Online Library
(wileyonlinelibrary.com).
Patient Characteristics
Patient characteristics are presented in Table II. Thirty-three
patients were enrolled on the study. One patient developed progress-
ive disease prior to study therapy and no further information is
reported. The median patient age was 7 years (range 1.75–18).
The median time from diagnosis to progressive disease prior to
HDCwas21months (range 3–120).Themedian time fromprogress-
ive disease to HDC was 3 months (range 1–10).
Eighteen patients hadMB, 15with a history ofmetastatic disease
within the CNS, including 10 with spinal drop metastases. Chang
staging for 17 patients for whom data are availablewereM0 (3), M2
(5), M3 (10). Other tumors included HGA (7), ependymoma (3),
rhabdoid tumor (2), supratentorial PNET (1), andpineoblastoma (1).
Twenty-five patients had residual disease at the time of HDC/SCR.
Twelve patients had bulky tumor (defined as >1 cm in greatest
diameter) at the time of HDC/SCR, including seven patients with
MB.
Study Design
ThestudywasaPhase I trial conductedby thePediatricBloodand
MarrowTransplantConsortium.Patientswere enrolled from1995 to
2002. Patients had collection of PBSC prior to study entry. PBSC
containing2  106CD34þ cells/kgwere infused on day 0 of each
cycle. The first HDC cycle included thiotepa IVover 3 hr followed
immediately by carmustine IVover 2 hr on days 5, 4, and 3.
Dexamethasone 4 mg/m2 daily PO or IVwas given on days5,4,
and3 in anattempt to prevent pulmonary toxicity fromBCNU.The
second HDC cycle included thiotepa IVover 3 hr followed immedi-
atelybycarboplatin IVover2 hrondays5,4,and3.Forpatients
with a creatinine clearance of <100 ml/min/1.73 m2, the dose of
carboplatinwascalculatedusingamodifiedCalvert formula [25,26].
The targetAUCusedwas7and5.5 mg min/ml for thecorresponding
doses of 500 and 400 mg/m2, respectively. The lower of the dose
calculated by per m2 dosing or by the modified Calvert formula was
used.
Cycle 2 commenced between 28 and 42 days after the PBSC
infusion of cycle 1 if: (1) ANC was 500/ml and platelets were
20,000/ml (could be with transfusion support); (2) non-hemato-
poietic toxicity has resolved sufficiently; (3) study eligibility criteria
for renal, hepatic, and pulmonary function were met at this time.
Local radiotherapy was allowed after the second PBSC cycle when
the platelet count reached 50,000/ml.
Dose Escalation and Maximum Tolerable Regimen
(MTR)
Dose escalation was planned as shown in Table III. Patients were
treated in cohorts of three. Toxicity was graded according to the
Children’sCancerGroupToxicity scale. If none of three patients had
dose-limiting toxicity (DLT), subsequent patients were enrolled at
the next dose level. If one out of three had DLT, then an additional
three patientswere enrolled at the samedose level. If twopatients at a
dose level hadDLT, then that level was deemed unacceptable and an
additional threepatientsweretreatedat thepreviouslevel.If<2outof
6 patients hadDLT, the dose levelwas considered tolerable.DLTwas
defined as: (1) severe organ dysfunction according to Bearman
criteria [27] lasting >7 days, or; (2) death attributable to regimen-
related toxicity occurring before day 28 following SCR (day 100 for
non-infectious pulmonary toxicity). Patients were considered not
assessable for determination of the MTR and were replaced if they
received only one HDC/SCR and did not have DLT.
When the protocol was amended to allow the enrollment of an
additional six patients at the MTR in order to better define the
pulmonary toxicity at this level and to modify the steroid dosing
during the conditioning regimen, the following rule was added. For
the six additional patients, if two experience DLT, the study will be
closed and the previousMTRwithout theminormodificationwill be
deemed the acceptable approach.
Clinical Monitoring and Intervention for Lung Disease
Because of pulmonary toxicity associated with high-dose car-
mustine, patients were monitored with handheld spirometry daily
and pulse oximetry weekly starting with cycle 1 and continuing for
4 weeks following cycle 2. A decrease in spirometry volume by
>10%or oxygen saturation (by>3%and/or to<95%)was followed
bypulmonaryfunctiontestingif thepatientcouldcomply.Significant
decreases in lung volumes or diffusion capacity were treated with
prednisone1–2 mg/kg/day,whichcouldbe taperedover2months (as
tolerated) following improvement.
Statistical Analysis
Overall and event-free survival was calculated from the day of
SCR after the first HDC cycle. The survivor function was estimated
bythemethodofKaplanandMeier[28].Survivalcurveswerecreated
using the program R (R Development Core Team, Vienna, Austria).
RESULTS
Therapy
Seven patients received only one cycle of HDC/SCR because of
severe toxicity (1), toxic death (3), disease progression (1), and
parental request without severe toxicity (2). Two patients received
RT for residual disease after HDC/SCR (one craniospinal and one
local RT) as allowed by the protocol. Two patients received temo-
zolomide after recovery from HDC/SCR because of bulky residual
disease.
Toxicity
Common toxicities included mucositis, emesis, diarrhea, ano-
rexia, and pancytopenia.Mucositis was usuallymild tomoderate; 5/
32 patients had grade 3–4 mucositis. Mucositis was usually more
severe after the second cycle. Emesis and diarrheawere usuallymild
to moderate; 2/32 patients had grade 3–4 diarrhea and 1 patient had
grade 4 emesis. Anorexia frequently required parenteral nutrition.
Twelve bacterial infections occurred in nine patients, including
TABLE I. ComparisonofDrugDosesBetweenThisStudyandPrior
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bacteremia (8 gram positive and 3 gram negative) and one catheter-
related Pseudomonas cellulitis.
Grade 3–5 toxicities and grade 2 pulmonary toxicity treated with
steroids are shown in Table IV.Nopatient had non-fatal severe organ
dysfunction lasting >7 days. Eight patients (25%) had regimen-
related deaths. The cause of death was pulmonary failure (n ¼ 4,
including two with pulmonary hypertension), pulmonary and renal
failure (n ¼ 2), renal failure (n ¼ 1), and severehepatic veno-occlu-
sive disease (VOD) with multi-organ failure (MOF) (n ¼ 1). Fatal
pulmonary toxicitywasmore commonat dose level 1, occurring in4/
9 patients at this level compared to 2/23 patients at the other dose
levels. Non-fatal pulmonary toxicity occurred in eight patients. Four
patients had restrictive lung disease without an oxygen requirement
and four patients required oxygen. One episode was associated with
cytomegalovirus reactivationandoneepisodethatoccurred5months
after HDC/SCR was associated with Pneumocystis jirovecii after
craniospinal RT. The non-infectious cases resolved with steroid
therapy. Three patientswho required steroids for pulmonary toxicity
after cycle1, tolerated cycle2anddidwell long-term.Seven subjects
had grade 3–4 neurotoxicity, one with concomitant VOD. Severe
neurological toxicity included coma (2), seizures (3), ataxia (1), and
weakness/lethargy (1). Three patients with pre-existing sensorineu-
ral hearing loss (SNHL) had worsening SNHL after HDC/SCR.
Dose Escalation
Two of six assessable patients at dose level 1 had DLT. Both had
MOF, onewithVOD.Three additional patients treated at dose level 1
were considered not assessable for the purpose of determining the
MTR.Onepatient receivedonlythefirstHDC/SCRcycleperparental
request. Two patients had very complicated histories and clinical
courses that confounded the role ofHDC in their deaths. One patient
died due to aspiration pneumonia and with refractory seizures pre-
sumedtobeduetoafamilial seizuredisorder thathadalsoclaimedthe
life of his sister. The secondpatient hadpulmonary failure associated
with aspiration 3weeks following cycle 1 after esophageal dilatation
for a chronic stricture.
The dose level was de-escalated to level 0 by reducing the
carboplatin dose in cycle 2. As the fatal pulmonary toxicities seen
at dose level 1 occurred soon after course 2 chemotherapy, we
attributed them to the intensity of cycle 2 therapy and not to the
nitrosourea.We therefore kept the nitrosourea dose the same in dose
level 0 as in dose level 1. After 3/3 assessable patients tolerated dose
level 0, the dose level was then escalated to dose level 2a (modifi-
cation of the original dose level 2 using the reduced carboplatin dose
of level 0 with an increase in the thiotepa dose during cycle 2). Only
oneof threeassessablepatients treatedatdose level 2ahadDLT, soan
additional three patients were enrolled. Because of previous experi-
encewith somepatients not being assessable, two additional patients
were enrolled in anticipation of the need for replacement patients.
When two of the first six had DLT (one VOD with MOF and one
pulmonary failure), dose level 2a was deemed unacceptable. The
additional two patients did not have DLT.
Dose level 0 was further evaluated with the enrollment of an
additional three patients according to the study design. None of the
firstsixpatientsatdoselevel0hadDLT.Because2/6patientshadnon-
fatal pulmonary toxicity requiring steroid therapy, an additional six
patients were enrolled at dose level 0 to better define the risk of
pulmonary toxicity. In addition, steroid therapy during carmustine
administrationwas increased fromdexamethasone4 mg/m2dailyon
day 5 to day 3 to 4 mg/m2 twice daily on day 5 to day 1 for
these patients in an attempt to prevent pulmonary toxicity. Despite
this change, two of these six children had DLT (one MOF and one
pulmonary failure).BothpatientswithDLThadPseudomonas infec-
tions; one episodewas between cycles 1 and 2 and the other followed
cycle2. It is possible that theadditional steroid therapycontributed to
TABLE III. Dose Escalation Schema
Dose level First cycle Second cycle
Level 0 Thiotepa 600 mg/m2 Thiotepa 600 mg/m2
BCNU 300 mg/m2 Carboplatin 1,200 mg/m2
Level 1 Thiotepa 600 mg/m2 Thiotepa 600 mg/m2
BCNU 300 mg/m2 Carboplatin 1,500 mg/m2
Level 2a Thiotepa 600 mg/m2 Thiotepa 750 mg/m2
BCNU 300 mg/m2 Carboplatin 1,200 mg/m2
Level 3a Thiotepa 750 mg/m2 Thiotepa 750 mg/m2
BCNU 300 mg/m2 Carboplatin 1,200 mg/m2
Level 4a Thiotepa 750 mg/m2 Thiotepa 750 mg/m2
BCNU 450 mg/m2 Carboplatin 1,200 mg/m2
The dose escalated at each level is shown in bold. The original dose of
carboplatin for levels 2–4was 1,500 mg/m2. However, because of dose-
limiting toxicity at level 1 (see text), the dose of carboplatin was
decreased when therapy was de-escalated to dose level 0. The dose of
carboplatin remained at 1,200 mg/m2 for the amended dose levels 2–4.
TABLE IV. Severe Toxicities by Dose Level
Dose
level Pulmonary Hepatic Renal Neurological MOF Infection Mucositis GI Skin
0 5/13
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MOF, multi-organ failure; GI, gastrointestinal. Severe toxicities include grade 3–5 toxicities and grade 2 pulmonary toxicities requiring steroid
therapy;grade5 toxicity is fatal.Multi-organ failure includespatients inwhomtheprimarycauseofdeathwashepatic (i.e., veno-occlusivedisease) or
pulmonary failure. Two of the four fatal pulmonary toxicities at dose level 1 were judged to not be related to study therapy (see text).
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the toxic deaths by causing increased immunosuppression. Overall,
2/12 assessable patients treated at dose level 0 hadDLTand the toxic
death rate was 17%.
Patient Outcome
Thirty-twopatients receivedprotocol therapy.Althoughthestudy
was a Phase I study to determine an acceptable treatment regimen,
long-term outcome data are available. Seven children remain alive
and without disease, including 5/18 with MB (135, 92, 87, 83, and
54 months after HDC/SCR) and both patients with rhabdoid tumors
(100 and90months afterHDC/SCR).Allfive survivingpatientswith
MB had metastatic disease prior to HDC/SCR, including three with
spinal leptomeningeal disease. All of them had received RT prior to
HDC/SCR—craniospinal (two at diagnosis and one at disease pro-
gression) or local (one at diagnosis and one at disease progression).
Only one of themhad bulkdisease at the time ofHDC.This patient is
alive and well 87 months after HDC, despite progressive disease
34 months after HDC. The patient had resection of a large drop
metastasis that confirmed relapsed MB. Following surgery, the
patient was treated with chemotherapy and local radiotherapy.
Eighteen patients had progressive disease at a median of 12 months
after HDC/SCR (range 1–48).
Progression-free and overall survival curves are shown in
Figure 1. The Kaplan–Meier estimates of EFS and overall survival
at3years forallpatients are25%(95%CI14–46%)and38%(95%CI
24–59%).TheKaplan–MeierestimatesofEFSandoverall survivalat
3 years for patients with MB are 28% (95% CI 13–58%) and 44%
(95% CI 26–74%).
DISCUSSION
HDC/SCRhas been shown tobe beneficial for somepatientswith
recurrentbrain tumors,with3-yearEFSof30%insomereports [2].
We conducted a Phase I trial of tandem cycles ofHDC. The intensity
of each myeloablative cycle was reduced to avoid excessive cumu-
lativeorgan toxicity.Thefirst cyclewas intended tobecytoreductive,
allowingthesecondcycle tobedeliveredata timeofminimalresidual
disease. Another unique feature of the regimen is that alkylating
agents were given on the same days rather than on sequential days as
in previous trials of HDC/SCR. The hypothesis was that efficacy
would be increased by achieving higher peak alkylator levels and
toxicitywould be decreased (especiallymucositis) due to the shorter
duration of exposure. A dose-escalation study design was used to
determine doses with acceptable acute and cumulative toxicities.
Theuseof twocyclesof thiotepaallowed the total thiotepadose to
be escalated from900 mg/m2aspreviously reportedwithHDC/SCR
for brain tumors [8] to 1,200 mg/m2. However, carboplatin dosing
had to be reduced compared to that previously reported [10]. The
incidence of pulmonary toxicity was higher than expected for car-
mustine at the dosegiven [29]. The latter twofindingsmayhave been
related to giving the alkylating agents on the same day.
The tandemHDC/SCR therapywas associatedwith considerable
toxicity. Pulmonary toxicity was a major limitation of this therapy,
occurring in 44% of patients. It should be noted that our assessment
for pulmonary toxicity is intentionally very inclusive and includes
patients with aspiration pneumonia, infections, and post-infectious
complications that likelywere not directly due to the specific chemo-
therapy used. A similar 45% incidence of pulmonary toxicity was
reportedforamyeloablativeregimencontainingcarmustine600 mg/
m2, thiotepa, and etoposide for childrenwith newly diagnosed HGA
[24]. In our study, pulmonary toxicity occurred at all dose levels, but
was most severe at dose level 1. There was only 1 fatal pulmonary
toxicityoutof13patientsat theMTR(dose level0)andthiswasdueto
pulmonary hypertension followingPseudomonas sepsis. An associ-
ation between either gender or prior craniospinal irradiation and
nitrosourea-related pulmonary toxicity has been previously
described. We found no statistical association between pulmonary
toxicity and either gender (P ¼ 1) or prior spinal irradiation
(P ¼ 0.5).
Fig. 1. A:Event-free survival (- - -) andoverall survival (___) from thedayofSCRafter thefirstHDCcycle for all 32patients and (B) for 18patients
with medulloblastoma.
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Neurotoxicity occurred in 22% of patients and was similar at all
dose levels. Neurotoxicity has been reported at similar frequencies
with other regimens for brain tumors—30% with busulfan and
thiotepa [30] and 22% with etoposide, thiotepa, and carboplatin
[10]. Grade 3–4 hepatotoxicity occurred in 6% of patients, which
compares favorably to 25% reported with busulfan and thiotepa [9]
and 56% reported with etoposide, thiotepa, and carboplatin [10].
Severe renal toxicity occurred in 6%patients, similar to that reported
with etoposide, thiotepa, and carboplatin [10].Mucositis and gastro-
intestinal toxicity were less common than reported with other regi-
mens for recurrent brain tumors [10,11]. This finding supports our
hypothesis that fewer days of chemotherapy administration would
reduce mucosal toxicity.
Three patients had worsening SNHL after HDC/SCR. All had
medullobastoma, had received craniospinal irradiation with
posterior fossa boost, and had SNHL prior to HDC/SCR. The
relationship to prior therapy has been reported with other high-dose
carboplatin regimens [21].
Our tandemHDC/SCR regimen resulted in similar toxicities to a
single cycle of etoposide, thiotepa, and carboplatin [3,10]. Possible
advantages of the tandem regimen include less severe mucositis
and less grade 3–4 hepatic toxicity. Unfortunately, the toxic death
rate of 25% in our Phase I trial was similar to Phase II trials using
one cycle of HDC which reported rates of 11–22% [10,12,18,31].
It should be noted that the toxic death rate in our study was 17% at
the MTR and 0% for the six patients treated at the MTR without
the additional steroid therapy (as discussed above). More recent
studies have demonstrated toxic mortality rates declining to below
10% [32]. We would point out that our study was conducted
between 1995 and 2002. As suchwewould attribute the discrepancy
between the toxic death rates in contemporary studies and in ours
to ongoing improvements in supportive care for such heavily pre-
treated patients.Also, the toxic death rate in our Phase I study and the
toxic death rates from Phase II studies are difficult to compare
because there are likely significant differences in the disease status
and prior therapy between patients treated on these different types of
studies.
A preliminary assessment of efficacy is possible although it must
be noted that this is in the context of a Phase I trial that was not
designed to look at efficacy. The 3-year actuarial event–free survival
(EFS) for patients with MB was 28% (5/18). All five surviving
patients withMB hadmetastatic disease prior to HDC/SCR, includ-
ing three with spinal leptomeningeal disease. All of them had
received RT prior to HDC/SCR—craniospinal (two at diagnosis
and one at disease progression) or local (one at diagnosis and one
at disease progression). Of course, the RT at disease progression
could have contributed to the long-term disease control. Efficacy of
our approach is also suggested by the prolonged progression-free
interval experienced by a significant number of patients. In addition
to the long-term survivors, 36% of patients had progression-free
intervals of at least 1 year after SCR including 5/13 patients with
MB (13, 18, 18, 18, 48months), 3/6with glioblastomamultiforme or
HGA (12, 23, and 43 months), and 1/3 with ependymoma (12
months). Of note, only two of these patients received additional
therapy during the progression-free interval. One patient received
craniospinal RTwith a local boost for residual disease as allowed per
protocol.Theotherpatient received temozolomide for residualbulky
disease.
Thediscussionofefficacyisverycomplicatedbasedonnumerous
factors. This study was one of the few Phase I dose escalation trials
performed for HDC/SCR in children. Most studies have used fixed
dosesofchemotherapyforpilotorPhaseII studies.Becauseourstudy
was a Phase I trial of a novel chemotherapy regimen, we had an
extremely high-risk cohort of patients. For example, 15/18 MB
patients hadmetastatic disease and 7/18 had bulk disease at the time
of transplant.Also, of thefive long-termsurvivorswithMB, threedid
not have biopsy of recurrent disease or neurological symptoms at the
time of recurrence. These three patients had recurrence at 9, 14, and
21months after diagnosis. It is possible that someof the radiographic
relapses represented imaging changes rather than disease. Of note,
Dunkel et al. [15] did not find a statistically significant difference in
EFS for patients with MRI evidence of recurrent MB versus those
with tissue confirmation of recurrence. Interestingly, our results are
remarkably similar to thoseofDunkel for patientswith recurrentMB
[10,15].
Thirteenof18patientswithMBhad received radiotherapy aspart
of their initial treatment. Three of 13 (23%) previously irradiated
patients and 2/5 (40%) non-irradiated patients survive. It should be
noted that some studies have demonstrated similar survival rates in
previously irradiated patients [13,15], whereas others have reported
dismal results in such patients [16,17,33].
TandemHDC/SCR did not overcome the impact of bulk disease.
At dose level 0, the maximum tolerated regimen, disease-free sur-
vival is 3/5 patients without bulk disease compared to 0/4 with bulk
disease at the time of HDC. Bulk disease has been correlated with
poor outcome in most HDC/SCR studies [32].
Metastatic disease at HDC/SCR for patients with MB is
another poor prognostic factor. In a study of etoposide, thiotepa,
and carboplatin for recurrent MB, the 3-year EFS was 26% for
patients with M1þ disease and 60% for patients with M0 disease
[10]. Similarly, a report of melphalan and cyclophosphamide for
recurrentMBhad 4/4 patients surviving after HDC/SCR for patients
with relapse isolated to the posterior fossa, but 0/14 survivors with
M2þdisease [11]. Inour study,5/15 (33%)patientswithM2þdisease
remain alive with follow-up of 54–135 months.
The two long-term survivors with rhabdoid tumors are note-
worthy in light of the very poor prognosis for such patients.
One patient had intracranial metastases at the time of progression
and had received craniospinal RT at initial diagnosis. The
other patient had bulky disease at the primary site at the time of
HDC. This patient received only local RT after HDC/SCR because
of young age. Finally, despite prolonged time to progression in
three patients with glioblastoma multiforme, the long-term
survival for patients with HGA and other histologies was poor.
This is similar to the experience for these tumors reportedwith other




thiotepa and carboplatin for the second cycle. Although mucositis
and hepatotoxicity were less common and less severe compared to
reports of single cycleHDC/SCR, pulmonary toxicitywas consider-
able and the toxic death rate was not improved compared to that of a
single cycle of HDC/SCR in patients with recurrent disease per-
formed during the same time period. If a Phase II study with chemo-
therapy at theMTR is performed in the future, it will be important to
closelymonitor pulmonary toxicity and tohave appropriate stopping
rules for toxicity. The tandem regimen appears to have significant
activity against brain tumors, particularly medulloblastomas and
rhabdoid tumors.
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